- |||||||||| TY-2699a is a highly potent CDK7 inhibitor to abolish dysfunctional tumor cell cycle for clinical development (Section 9; Poster Board #10) - Mar 14, 2023 - Abstract #AACR2023AACR_8576;
P1
Currently, trilaciclib, palbociclib, ribociclib, and abemaciclib that bear dual specificities against CDK4 and CDK6 have been approved for clinical usage, and more CDK4/6 targeted agents are actively under clinical evaluations, among which, TY-302, a novel CDK4/6 inhibitor being developed by TYK Medicines, is under Phase II trial (NCT04433494)...Several CDK7 targeted agents, such as SY-5609 and Samuraciclib (CT7001), are under development...# Shengli Dong and Apeng Liang contributed equally to this work. * Jun Li, Shengli Dong and Apeng Liang are the correspondent authors.
- |||||||||| TY-302 / TYK Medicines
Trial completion date, Trial primary completion date, Metastases: A Study of TY-302 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 7, 2022
P1, N=60, Recruiting,
* Jun Li, Shengli Dong and Apeng Liang are the correspondent authors. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> May 2023
- |||||||||| TY-302 / TYK Medicines
Enrollment open, Metastases: A Study of TY-302 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 17, 2022
P1, N=60, Recruiting,
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: May 2022 --> May 2023 Not yet recruiting --> Recruiting
|
